Dyskinesia is a term used to describe a wide range of involuntary movements. It occurs when the natural brain function is disrupted, leading to difficulty controlling body movements. It is most often seen in people with neurological disorders such as Parkinson’s disease, Huntington’s disease, and multiple system atrophy. Dyskinesia can result from certain medications or can be a side effect of a degenerative neurological disorder, such as those mentioned above. The symptoms of dyskinesia can vary from person to person, ranging from twitching or involuntary jerking of the limbs during activities such as walking or writing, to more severe forms, such as uncontrollable movements or even tongue thrusting. In the most severe cases, the individual’s ability to move may be severely impaired, and they may even have difficulty speaking. Physicians can diagnose dyskinesia through physical examination and medical tests. Treatment usually involves medications such as dopamine agonists, which boost dopamine levels in the brain, or anticholinergic drugs, which reduce muscle spasms and involuntary movements. In addition, physical therapy, occupational therapy, and speech therapy may also be used to help improve muscle control and coordination. Dyskinesia can have a significant impact on quality of life, as it can cause difficulties with everyday activities such as self-care, mobility, and communication. People with dyskinesia may feel embarrassed or self-conscious about their movements, leading to social isolation and feelings of depression and anxiety. It’s important to seek treatment and continue with physical and occupational therapy to help manage the symptoms. It is also important to understand the underlying cause of the condition in order to determine the best course of treatment. With proper care and treatment, people with dyskinesia can lead productive and fulfilling lives.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom